Amway (China) R&D Center
Works in Dermatology · Genetic & rare · Metabolic & endocrine · Musculoskeletal · Neurology
Amway (China) R&D Center is a clinical trial sponsor. It has 1 active clinical trial with 200 planned participants, across 5 therapeutic areas. Since 2021 it has completed 4 trials and stopped 0 early.
Trial track record · since 2021
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Amway (China) R&D Center
Amway (China) R&D Center is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 200 planned participants, in Dermatology, Genetic & rare, Metabolic & endocrine, Musculoskeletal and other areas. Since 2021 it has completed 4 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Amway (China) R&D Center; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-07-08.
Approve Suite is not affiliated with Amway (China) R&D Center.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.